

Peter M Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5203875/publications.pdf>

Version: 2024-02-01

156
papers

8,051
citations

38742

50
h-index

56724

83
g-index

165
all docs

165
docs citations

165
times ranked

10228
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice. <i>Science Translational Medicine</i> , 2013, 5, 206ra138.	12.4	480
2	Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 464-479.	46.4	376
3	<i>In vitro</i> and <i>in vivo</i> antitumor properties of the cyclin dependent kinase inhibitor CYC202 (Roscovitine). <i>International Journal of Cancer</i> , 2002, 102, 463-468.	5.1	371
4	Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. <i>Cell Death and Disease</i> , 2015, 6, e1672-e1672.	6.3	260
5	Mutations in a translation initiation factor identify the target of a memory-enhancing compound. <i>Science</i> , 2015, 348, 1027-1030.	12.6	195
6	Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 302-313.	8.7	192
7	Diketopiperazines in peptide and combinatorial chemistry. <i>Journal of Peptide Science</i> , 2003, 9, 9-35.	1.4	187
8	4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6500-6509.	6.4	166
9	Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B. <i>Science</i> , 2018, 359, 1533-1536.	12.6	157
10	2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1662-1675.	6.4	156
11	Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics. <i>Current Medicinal Chemistry</i> , 2000, 7, 1213-1245.	2.4	149
12	Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. <i>Chemical Biology and Drug Design</i> , 2000, 55, 163-172.	1.1	146
13	Structure of Free MDM2 N-terminal Domain Reveals Conformational Adjustments that Accompany p53-binding. <i>Journal of Molecular Biology</i> , 2005, 350, 587-598.	4.2	132
14	Cellular Delivery of Impermeable Effector Molecules in the Form of Conjugates with Peptides Capable of Mediating Membrane Translocation. <i>Bioconjugate Chemistry</i> , 2001, 12, 825-841.	3.6	127
15	In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202. <i>Clinical Cancer Research</i> , 2005, 11, 4875-4887.	7.0	127
16	Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 1871-1876.	7.1	121
17	The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases. <i>Current Medicinal Chemistry</i> , 2004, 11, 1563-1583.	2.4	116
18	Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS. <i>Structure</i> , 2003, 11, 399-410.	3.3	115

#	ARTICLE	IF	CITATIONS
19	The Design, Synthesis and Application of Stereochemical and Directional Peptide Isomers: A Critical Review. <i>Current Protein and Peptide Science</i> , 2003, 4, 339-356.	1.4	115
20	Progress in the Discovery of Polo-like Kinase Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 181-197.	2.1	114
21	Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 457-477.	4.1	112
22	Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 640-659.	6.4	111
23	CDK inhibitors in clinical development for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 955-970.	4.1	107
24	Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. <i>Scientific Reports</i> , 2017, 7, 14542.	3.3	93
25	Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. , 2006, 2, 608-617.		92
26	Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents. <i>Chemistry and Biology</i> , 2010, 17, 1111-1121.	6.0	92
27	Discovery of <i>N</i> -Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4367-4378.	6.4	91
28	PPP1R15A-mediated dephosphorylation of eIF2 γ is unaffected by Sephin1 or Guanabenz. <i>ELife</i> , 2017, 6, .	6.0	88
29	New Lupane Derived Compounds with Pro-Apoptotic Activity in Cancer Cells: Synthesis and Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5402-5415.	6.4	83
30	Small-molecule inhibitors of MDM2 as new anticancer therapeutics. <i>Seminars in Cancer Biology</i> , 2010, 20, 10-18.	9.6	80
31	Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. <i>International Journal of Cancer</i> , 2012, 131, 2433-2444.	5.1	79
32	A Quantitative Study of the in Vitro Binding of the C-Terminal Domain of p21 to PCNA: Affinity, Stoichiometry, and Thermodynamics. <i>Biochemistry</i> , 2000, 39, 7388-7397.	2.5	78
33	2-[(1-Methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 143-151.	4.1	75
34	Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 343-346.	8.7	74
35	A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. <i>Oncotarget</i> , 2014, 5, 375-385.	1.8	73
36	Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: Progress 2001-2006. <i>Medicinal Research Reviews</i> , 2007, 27, 755-795.	10.5	69

#	ARTICLE	IF	CITATIONS
37	Crystallographic and Mass Spectrometric Characterisation of eIF4E with N7-alkylated Cap Derivatives. <i>Journal of Molecular Biology</i> , 2007, 372, 7-15.	4.2	68
38	Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. <i>Medicinal Research Reviews</i> , 2017, 37, 314-367.	10.5	65
39	Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. <i>British Journal of Cancer</i> , 2011, 104, 653-663.	6.4	63
40	Cap in hand: Targeting eIF4E. <i>Cell Cycle</i> , 2009, 8, 2535-2541.	2.6	62
41	Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 114, 38-42.	4.3	61
42	Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4237-4240.	2.2	60
43	Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors. <i>Chemistry and Biology</i> , 2004, 11, 525-534.	6.0	59
44	Strategies for the Design of Potent and Selective Kinase Inhibitors. <i>Current Pharmaceutical Design</i> , 2005, 11, 1845-1863.	1.9	58
45	Differential Binding of Inhibitors to Active and Inactive CDK2 Provides Insights for Drug Design. <i>Chemistry and Biology</i> , 2006, 13, 201-211.	6.0	58
46	Design, Synthesis, and Structure-Activity Relationship Exploration of 1-Substituted 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one Analogues as Inhibitors of the Annexin A2-S100A10 Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2080-2094.	6.4	58
47	Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and Δ^9 -tetrahydrocannabinol in rat plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 145-151.	2.8	56
48	CDK17, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. <i>International Journal of Cancer</i> , 2012, 130, 1216-1226.	5.1	54
49	Highly potent p21WAF1-derived peptide inhibitors of CDK-mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin-A. <i>Chemical Biology and Drug Design</i> , 2002, 60, 257-270.	1.1	53
50	Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. <i>Organic and Biomolecular Chemistry</i> , 2004, 2, 2735.	2.8	53
51	Insights into Cyclin Groove Recognition. <i>Structure</i> , 2003, 11, 1537-1546.	3.3	52
52	Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isoselectivity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 660-670.	6.4	51
53	Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 1763-1771.	5.4	50
54	Protein Structures in Virtual Screening: A Case Study with CDK2. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 92-104.	6.4	48

#	ARTICLE	IF	CITATIONS
55	Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. <i>Oncotarget</i> , 2014, 5, 7691-7704.	1.8	48
56	Coagulation factor XII protease domain crystal structure. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 580-591.	3.8	48
57	Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 3448-59.	0.0	47
58	Design, synthesis and SAR exploration of tri-substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interaction. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5378-5391.	3.0	46
59	Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 447-455.	5.5	45
60	Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system. <i>Journal of Controlled Release</i> , 2018, 286, 10-19.	9.9	41
61	The Use of CDK Inhibitors in Oncology: A Pharmaceutical Perspective. <i>Cell Cycle</i> , 2004, 3, 740-744.	2.6	40
62	REPLACE: A Strategy for Iterative Design of Cyclin-Binding Groove Inhibitors. <i>ChemBioChem</i> , 2006, 7, 1909-1915.	2.6	40
63	Peptidomimetic Design of CDK Inhibitors Targeting the Recruitment Site of the Cyclin Subunit. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003, 3, 57-69.	7.0	39
64	Small molecules that bind the Mdm2 RING stabilize and activate p53. <i>Carcinogenesis</i> , 2012, 33, 791-798.	2.8	38
65	Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters. <i>Molecular Pharmaceutics</i> , 2015, 12, 3389-3398.	4.6	38
66	The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics. <i>Mini-Reviews in Medicinal Chemistry</i> , 2003, 3, 257-270.	2.4	37
67	Turning the key on p53. <i>Nature</i> , 2004, 427, 789-790.	27.8	37
68	Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. <i>Tetrahedron: Asymmetry</i> , 2001, 12, 2891-2894.	1.8	35
69	Pharmacological targeting of lysine acetyltransferases in human disease: a progress report. <i>Drug Discovery Today</i> , 2007, 12, 88-99.	6.4	35
70	Efficient Palladium-Catalyzed Cross-Coupling of β^2 -Chloroalkylidene/arylidene Malonates Using Microwave Chemistry. <i>Journal of Organic Chemistry</i> , 2004, 69, 6920-6922.	3.2	34
71	Three-Dimensional Pharmacophore Design and Biochemical Screening Identifies Substituted 1,2,4-Triazoles as Inhibitors of the Annexin A2-S100A10 Protein Interaction. <i>ChemMedChem</i> , 2012, 7, 1435-1446.	3.2	34
72	Liquid-phase peptide synthesis on polyethylene glycol (PEG) supports using strategies based on the 9-fluorenylmethoxycarbonyl amino protecting group: application of PEGylated peptides in biochemical assays. <i>Journal of Peptide Science</i> , 2002, 8, 529-542.	1.4	33

#	ARTICLE	IF	CITATIONS
73	Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53â€“HDM2 Proteinâ€“Protein Interaction. <i>International Journal of Peptide Research and Therapeutics</i> , 2006, 12, 3-19.	1.9	33
74	Molecular profiling and combinatorial activity of <sc>CCT</sc>068127: a potent <sc>CDK</sc>2 and <sc>CDK</sc>9 inhibitor. <i>Molecular Oncology</i> , 2018, 12, 287-304.	4.6	33
75	Support Tools in Formulation Development for Poorly Soluble Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2260-2269.	3.3	32
76	Design, Synthesis, and Evaluation of 2-Methyl- and 2-Amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as Ring-Constrained 2-Anilino-4-(thiazol-5-yl)pyrimidine Cyclin-Dependent Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2136-2145.	6.4	31
77	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6949-6965.	3.0	31
78	Immunosuppressive but Non-LasR-Inducing Analogues of the <i>Pseudomonas aeruginosa</i> Quorum-Sensing Molecule <i>N</i>-(3-Oxododecanoyl)-<sc>l</sc>-homoserine Lactone. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3348-3359.	6.4	30
79	End-stapled homo and hetero collagen triple helices: a click chemistry approach. <i>Chemical Communications</i> , 2011, 47, 2589-2591.	4.1	29
80	A facile approach to tryptophan derivatives for the total synthesis of argyrin analogues. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 9764-9768.	2.8	27
81	Application of t-butyltrimethylsilyl ethers of serine, threonine and tyrosine in peptide synthesis. <i>Tetrahedron Letters</i> , 1992, 33, 7605-7608.	1.4	25
82	A fluorescence-based assay suitable for quantitative analysis of deadenylase enzyme activity. <i>Nucleic Acids Research</i> , 2014, 42, e30-e30.	14.5	25
83	Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach. <i>Journal of Controlled Release</i> , 2021, 329, 1077-1089.	9.9	25
84	Active Site Pressurization: A New Tool for Structure-Guided Drug Design and Other Studies of Protein Flexibility. <i>Journal of Chemical Information and Modeling</i> , 2008, 48, 1448-1454.	5.4	24
85	CDK versus GSK-3 Inhibition. <i>Chemistry and Biology</i> , 2003, 10, 1144-1146.	6.0	23
86	Unexpected lability of cysteine acetamidomethyl thiol protecting group Tyrosine ring alkylation and disulfide bond formation upon acidolysis. <i>Chemical Biology and Drug Design</i> , 1997, 49, 341-346.	1.1	23
87	Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 200-217.	5.5	23
88	Solution synthesis of a dimeric pentapeptide: Diketopiperazine cyclisation of Glu-Asp dipeptide esters and Asp-racemisation during segment condensation. <i>Tetrahedron</i> , 1994, 50, 2277-2288.	1.9	22
89	Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3799-3822.	6.4	22
90	Computational chemistry approaches to drug discovery in signal transduction. <i>Biotechnology Journal</i> , 2008, 3, 452-470.	3.5	21

#	ARTICLE	IF	CITATIONS
91	A Versatile Polymer-Supported 4-(4-Methylphenyl(chloro)methyl)phenoxy Linker for Solid-Phase Synthesis of Pseudopeptides. <i>Journal of Organic Chemistry</i> , 2000, 65, 5048-5056.	3.2	20
92	Classical Anticytokinins Do Not Interact with Cytokinin Receptors but Inhibit Cyclin-dependent Kinases. <i>Journal of Biological Chemistry</i> , 2007, 282, 14356-14363.	3.4	20
93	Role of Key Transmembrane Residues in Agonist and Antagonist Actions at the Two Conformations of the Human β ₂ -Adrenoceptor. <i>Molecular Pharmacology</i> , 2008, 74, 1246-1260.	2.3	20
94	Synthesis and in Vitro and in Vivo Characterization of Highly β ₁ -Selective β ₂ -Adrenoceptor Partial Agonists. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3852-3865.	6.4	20
95	New approaches to cancer therapies. <i>Journal of Pathology</i> , 1999, 187, 138-146.	4.5	19
96	Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 162, 43-49.	4.3	19
97	Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-Site: structural variants of the C-Terminal Phe. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2501-2505.	2.2	18
98	Direct immunization with synthetic peptidyl-polyamide resin. <i>Journal of Immunological Methods</i> , 1989, 118, 119-123.	1.4	17
99	Truncation and Optimisation of Peptide Inhibitors of Cyclin-Dependent Kinase 2-Cyclin A Through Structure-Guided Design. <i>ChemMedChem</i> , 2009, 4, 1120-1128.	3.2	17
100	A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin. <i>Scientific Reports</i> , 2019, 9, 15760.	3.3	17
101	Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2628-2631.	2.2	16
102	5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6868-6877.	3.0	16
103	Novel selective β ₁ -adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. <i>FASEB Journal</i> , 2017, 31, 3150-3166.	0.5	16
104	Development of Cordycepin Formulations for Preclinical and Clinical Studies. <i>AAPS PharmSciTech</i> , 2017, 18, 3219-3226.	3.3	16
105	Simple and sensitive HPLC-UV method for determination of bexarotene in rat plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1040, 73-80.	2.3	16
106	A Cyclic Pentapeptide Derived from the Second EGF-Like Domain of Factor VII Is an Inhibitor of Tissue Factor Dependent Coagulation and Thrombus Formation. <i>Thrombosis and Haemostasis</i> , 2002, 87, 13-21.	3.4	15
107	Solid-phase peptide synthesis without side-chain hydroxyl protection of threonine. <i>International Journal of Peptide and Protein Research</i> , 1991, 38, 491-493.	0.1	15
108	Cyclin-dependent kinase inhibitors: Discovery, development and target rationale for different therapeutic applications. <i>Drugs of the Future</i> , 2005, 30, 911.	0.1	15

#	ARTICLE	IF	CITATIONS
109	Direct Enzyme-Linked Immunosorbent Assay of Anti-Peptide Antibodies Using Capture of Biotinylated Peptides by Immobilized Avidin. <i>Journal of Immunoassay</i> , 1990, 11, 311-327.	0.3	14
110	In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. <i>Investigational New Drugs</i> , 2012, 30, 889-897.	2.6	14
111	Investigation of the Flexibility of Protein Kinases Implicated in the Pathology of Alzheimer's Disease. <i>Molecules</i> , 2014, 19, 9134-9159.	3.8	14
112	Crystal structures of the recombinant \hat{I}^2 -factor XIIIa protease with bound Thr-Arg and Pro-Arg substrate mimetics. <i>Acta Crystallographica Section D: Structural Biology</i> , 2019, 75, 578-591.	2.3	14
113	Identification of a novel toxicophore in anti-cancer chemotherapeutics that targets mitochondrial respiratory complex I. <i>ELife</i> , 2020, 9, .	6.0	14
114	Application of arylsulphonyl side-chain protected arginines in solid-phase peptide synthesis based on 9-fluorenylmethoxycarbonyl amino protecting strategy. <i>International Journal of Peptide and Protein Research</i> , 1992, 40, 19-24.	0.1	12
115	A Cy5-Labeled S100A10 Tracer Used to Identify Inhibitors of the Protein Interaction With Annexin A2. <i>Assay and Drug Development Technologies</i> , 2010, 8, 85-95.	1.2	12
116	Multiple Linear Regression Modeling To Predict the Stability of Polymer-Drug Solid Dispersions: Comparison of the Effects of Polymers and Manufacturing Methods on Solid Dispersion Stability. <i>Molecular Pharmaceutics</i> , 2018, 15, 1826-1841.	4.6	12
117	Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity <i>in Vivo</i> Mouse Model. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6784-6801.	6.4	12
118	Turning down tau phosphorylation. <i>Nature Chemical Biology</i> , 2008, 4, 448-449.	8.0	11
119	The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. <i>Cell Chemical Biology</i> , 2018, 25, 1107-1116.e4.	5.2	11
120	Efficient Synthesis of Differentially Protected (S,S)-2,7- Diaminooctanedioic Acid, the Dicarba Analogue of Cystine. <i>Helvetica Chimica Acta</i> , 1998, 81, 2053-2061.	1.6	10
121	Discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as inhibitors of the human poly(A)-selective ribonuclease Caf1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4219-4224.	2.2	10
122	Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113244.	5.5	10
123	Distribution of a highly lipophilic drug cannabidiol into different lymph nodes following oral administration in lipidic vehicle. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 174, 29-34.	4.3	10
124	Synthesis and activity of dimeric bradykinin antagonists containing diaminodicarboxylic acid bridge residues. , 1998, 4, 289-293.		9
125	Peptides corresponding to the second epidermal growth factor-like domain of human blood coagulation factor VII: synthesis, folding and biological activity. <i>Chemical Biology and Drug Design</i> , 1997, 50, 475-482.	1.1	9
126	Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle. <i>Pharmaceutics</i> , 2021, 13, 1349.	4.5	9

#	ARTICLE	IF	CITATIONS
127	Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120621.	5.2	8
128	The use of CDK inhibitors in oncology: a pharmaceutical perspective. <i>Cell Cycle</i> , 2004, 3, 742-6.	2.6	8
129	Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121947.	5.2	7
130	Formation of cyclized, including 3,5-cyclosteroid, alkenes from $\hat{1}^2, \hat{1}^3$ -unsaturated Grignard reagents induced by elimination of a $\hat{1}^1$ -alkoxy group. <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1987, , 475-479.	0.9	6
131	Synthetic peptide antigens of tetanus toxin. <i>Molecular Immunology</i> , 1994, 31, 1141-1148.	2.2	6
132	Synthesis of N $\hat{1}^{\pm}$ -(9-Fluorenylmethoxycarbonyl)-Allothreonine t-Butyl Ether via Threonine Oxazolines. <i>Tetrahedron Letters</i> , 1995, 36, 5409-5412.	1.4	6
133	Cell cycle inhibitors in cancer: current status and future directions. , 2008, , 253-283.		6
134	Exploiting glycogen synthase kinase 3 $\hat{1}^2$ flexibility in molecular recognition. <i>Biochemical Society Transactions</i> , 2008, 36, 55-58.	3.4	6
135	A Study of CDK2 Inhibitors Using a Novel 3D $\hat{1}^{\pm}$ QSAR Method Exploiting Receptor Flexibility. <i>QSAR and Combinatorial Science</i> , 2009, 28, 878-884.	1.4	6
136	Development and validation of a cost $\hat{1}^{\pm}$ effective and sensitive bioanalytical HPLC $\hat{1}^{\pm}$ UV method for determination of lopinavir in rat and human plasma. <i>Biomedical Chromatography</i> , 2020, 34, e4934.	1.7	6
137	Synthesis of N $\hat{1}^{\pm}$ -(9-fluorenylmethoxycarbonyl)-allothreonine t-butyl ether via threonine oxazolines. <i>Tetrahedron Letters</i> , 1995, 36, 5409-5412.	1.4	6
138	Analysis of 4-N,N-dimethylaminoazobenzene 4 $\hat{1}^{\pm}$ -thiohydantoin amino acids at sub-picomole levels by high-performance liquid chromatography: Simultaneous manual sequencing of picomole quantities of several polypeptides. <i>Analytical Biochemistry</i> , 1989, 177, 46-49.	2.4	5
139	Survival of the Fittest: Time-To-Event Modeling of Crystallization of Amorphous Poorly Soluble Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1858-1866.	3.3	5
140	GPCRs through the keyhole: the role of protein flexibility in ligand binding to $\hat{1}^2$ -adrenoceptors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 2604-2619.	3.5	5
141	Design of Low Molecular Weight Hemateregulatory Agents from the Structure $\hat{1}^{\pm}$ Activity Relationship of a Dimeric Pentapeptide. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 2876-2882.	6.4	4
142	Linear analogues derived from the first EGF-like domain of human blood coagulation factor VII: enhanced inhibition of FVIIa/TF complex activity by backbone modification through aspartimide formation. , 1999, 5, 323-329.		4
143	1 $\hat{1}^{\pm}$ Hydroxy $\hat{1}^{\pm}$ xanthine derivatives inhibit the human Caf1 nuclease and Caf1 $\hat{1}^{\pm}$ containing nuclease complexes via Mg 2+ $\hat{1}^{\pm}$ dependent binding. <i>FEBS Open Bio</i> , 2019, 9, 717-727.	2.3	3
144	Synthesis, biological activity, and solution structures of a cyclic dodecapeptide from the EGF-2 domain of blood coagulation factor VII. <i>Chemical Biology and Drug Design</i> , 2001, 57, 462-472.	1.1	2

#	ARTICLE	IF	CITATIONS
145	Using Esterase Selectivity to Determine the <i>In Vivo</i> Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β -Blockers. ACS Pharmacology and Translational Science, 2020, 3, 737-748.	4.9	2
146	Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents. Molecules, 2021, 26, 3327.	3.8	2
147	Cell cycle target validation: approaches and successes. Targets, 2003, 2, 154-161.	0.3	1
148	Application of anti-peptide antibodies to the assignment of the inter-chain disulphide bond in tetanus toxin. International Journal of Peptide and Protein Research, 1993, 41, 415-419.	0.1	1
149	A Peptide Sequence from Mouse Tissue Factor Inhibits Human Tissue Factor Dependent Factor X Activation. Thrombosis Research, 1998, 92, 135-140.	1.7	0
150	A Versatile Polymer-Supported 4-(4-Methylphenyl(chloro)methyl)phenoxy Linker for Solid-Phase Synthesis of Pseudopeptides.. Journal of Organic Chemistry, 2000, 65, 5076-5076.	3.2	0
151	Diketopiperazines in Peptide and Combinatorial Chemistry. ChemInform, 2003, 34, no.	0.0	0
152	Targeting the cell cycle. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 417-423.	0.5	0
153	Efficient Palladium-Catalyzed Cross-Coupling of α -Chloroalkylidene/Arylidene Malonates Using Microwave Chemistry.. ChemInform, 2005, 36, no.	0.0	0
154	Analytical techniques. Current Opinion in Chemical Biology, 2007, 11, 477-479.	6.1	0
155	Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate. Molecules, 2021, 26, 233.	3.8	0
156	Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 106-112.	4.3	0